Prediction of response to bromocriptine in acromegaly. by Atkinson, A. B. et al.
PREDICTION OF RESPONSE TO BROMOCRIPTINE
IN ACROMEGALY
by
A. B. ATKINSON, E. R. TRIMBLE, D. R. HADDEN and B. SHERIDAN
Metabolic Unit, Royal Victoria Hospital, Belfast
BROMOCRIPTINE was first used in the treatment of acromegaly in 1974
(Liuzzi et al, 1974 a). Not all patients show lowered human growth hormone in
response to the drug (Liuzzi et al, 1974 a; Thorner and Besser, 1975; Sachdev et al,
1975). We have performed a series of tests on acromegalic patients in an attempt to
discover if any test could predict those patients likely to show !ong-term response
to the drug.
MATERIAL AND METHODS
Eleven active acromegalics, eight with normal adrenal and thyroid status and
three on adequate replacement therapy, were studied. Three patients had had no
previous treatment. Three had undergone external pituitary irradiation, three
had had courses of chlorpromazine, one transfrontal hypophysectomy and another
transfrontal hypophysectomy followed by yttrium-90 implantation.
Each patient had a 50g oral glucose tolerance test (OGTT), a 30g arginine
infusion, and also an intravenous insulin tolerance test (0.3U/Kg) if the patient
had a normal pituitary-adrenal axis. All tests were performed between 9.00 and
11.00 a.m. Human growth hormone, hGH (except during arginine infusion),
glucose, insulin, secretin and glucagon were measured during each test by standard
radioimmunoassay techniques. Insulin-induced hypoglycaemia was considered
adequate if blood sugar fell to less than 50 per cent of the original value, and/or
there was a sharp rise in plasma cortisol.
Human growth hormone was measured hourly for 4 hours after a 2.5mg oral
dose of bromocriptine. Long-term treatment with bromocriptine was then com-
menced and dosage iAcreased gradually on the basis of random hGH estimations.
Dosages from 5 to 20mg daily were used. After three months the tests were
repeated.
RESULTS
Ten of the 11 patients reported subjective improvement varying from improved
wellbeing to increased muscle strength and diminished sweating. Five patients
experienced side effects. These were exacerbations of pre-existing Raynaud's
phenomenon (two patients) and nausea, epigastric discomfort and vasovagal
attack each occurring in one patient. In all cases side effects were mild, not neces-
sitating drug withdrawal.
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Fio. 1: Human growth hormone response during SOg oral glucose
tolerance test before and after bromocriptine therapy
(mean+S.E.).
Bromocriptine resulted in a marked fall in hGH levels during an oral GTT
(Fig. 1). Mean fasting levels fell (69.5mU/1 to 23.2mU/1) as did the levels at 60
and 90 minutes (75.4 and 80.8 to 32.6 and 29.8 respectively). These results were
statistically significant (P<0.05). Individual analysis showed that some patients
responded biochemically as measured by mean hGH during the second OGTT
while others failed to do so (Table 1). Biochemical response was defined as a fall
in mean plasma hGH during the second OGTT to less than 25 per cent of the
mean value during the first OGTT. This response showed no correlation with sella
size, length of history, previous mode of therapy or pattern of glucose response to
arginine infusion.
Fig. 2 shows pattern of hGH response to the first glucose load. We considered
whether those patients who suppressed partially during an OGTT might eventually
be either responders or non-responders. This was not so. Likewise, a paradoxical
rise in hGH during the oral GTT did not delineate response or non-response.
Fig. 3 shows the results following a 2.5mg test dosage of bromocriptine. In five
of seven patients the response to this was accurate as a prediction of eventual
response. In two cases, one a responder and another a non-responder, the test was
unhelpful. However, the test may still be of use (see below).
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values during first SOg oral glucose tolerance test in even-
tual biochemical responders and non-responders.
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FIG. 3: Human growth hormone response to a 2.5mg trial dosage
of bromocriptine showing correlation with eventual bio-
chemical response to long-term therapy with the drug.
R: eventual responders - NR: eventual non-responders.
Table 2 shows hGH response to insulin-induced hypoglycaemia. This was of
predictive value. Eventual responders showed a much more marked rise in hGH
than non-responders whose hGH level remained flat during the test. Is our small
group of patients it was uniformly predictive of eventual response to bromo-
criptine.
Our results also showed that in acromegalics mean glucagon-89, glucagon-57
and secretin were all within the normal range during both OGTTs (Table 3). When
biochemical responders and non-responders were analysed separately for each
glucose tolerance test, there was no variation so that neither bromocriptine nor
falling hGH affect circulating levels of these hormones. In responders there was a
fall in peak insulin during the second OGTT from 102 to 52uU/ml, probably on the
basis of a lower plasma glucose.
TABLE 2: HGH LEVELS DURING INSULIN-INDUCED HYPOGLYCAEMIA
hGH Maximal Value x 100
Patient hGH Fasting Maximal Fasting Fasting Value Category
M.B. 133 220 165 R
G.R. 100 176 176 R
S.A. 223 280 125 R
M.M. 14 220 1571 R
J.O'H. 31 34 109 NR
B.H. 38 40 105 NR
A.F. 142 146 103 NR
R: Responder. NR: Non-responder.
76TABLE 3: MEAN FASTING G.I. HORMONES BEFORE AND AFTER THERAPY
Before After
Glucagon-89 66.2 pg/ml 54.2 pg/ml
Glucagon-57 118.5 pg/ml 108.5 pg/ml
Secretin 15.2 pg/ml 12.7 pg/ml
Insulin 11.4 uU/ml 10.1 uU/ml
DISCUSSION
Wass et al (1977) reported that 21 per cent of a group of acromegalic patients
did not respond to bromocriptine. Sachev et al (1975) similarly reported two of 21
cases who showed no response. They also stated that the optimum therapeutic
daily dose was 20mg or less and that no further significant fall was seen in most
of those given higher dosage. Since bromocriptine is an expensive drug, we have
looked for possible means of predicting likely response to the drug in reasonable
dosage (less than 20mg daily).
Our results have shown that in seven cases out of seven the response to insulin-
induced hypoglycaemia was predictive. Patients who showed a marked response
in terms of rise in hGH became long-term responders, while those whose hGH
remained flat failed to do so. In another series (Liuzzi et al, 1974 b) response of
hGH to a test dosage of 2.5mg bromocriptine was compared with various tests,
including hypoglycaemia, but no uniform correlation was found. In that series
only a single dose of bromocriptine was assessed and an hGH "response" to hypo-
glycaemia was accepted only when the hGH level doubled. Although our results
show 100 per cent uniformity, this might well not be so in a larger series.
The bromocriptine test dosage may also be helpful in the long term; in our
series, five of seven were accurate predictors, while two were not. This test may
not be uniformly reliable or it may be that the two misleading cases were fortui-
tous. The eventual non-responder was still on a relatively small dose while the
other patient may not have been compliant in drug taking.
The question of using predictive tests before starting bromocriptine is unre-
solved. It may be that all patients on the drug show changes in ratios of molecular
sizes of growth hormone (Besser et al, 1976) or in somatomedin concentrations.
If this proves to be so, it would be worthwhile to treat all acromegalics who show
activity of the disease process. At present it remains our policy to give all patients
a trial of bromocriptine in reasonable dosage. We feel that both insulin-induced
hypoglycaemia and a 2.5mg oral dosage of the drug are useful in predicting likely
long-term response. If both tests suggest non-response, then at present it would
appear pointless to proceed to massive dosage of the drug.
SUMMARY
Eleven active acromegalics were studied before and after bromocriptine
therapy. Five clearly responded biochemically to the drug (mean hGH during
second OGTT less than 25 per cent of value obtained during first test). Four did
77not (mean 96-137 per cent of original) while response in two was doubtful (mean
65-75 per cent). Ten of the 11 claimed subjective improvement.
A four-hour profile of hGH following 2.5mg bromocriptine given orally pre-
dicted likely response to long-term treatment in five out of seven cases but in two
was misleading. hGH response to insulin-induced hypoglycaemia predicted
eventual response in all cases studied, a brisk rise (125-1500 per cent of fasting
levels) being seen in responders. Non-responders did not show this feature (103-
109 per cent).
Insulin-induced hypoglycaemia may be of value in predicting response to
bromocriptine though numbers studied are small.
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